Generic Cardizem LA Availability
CARDIZEM LA (diltiazem hydrochloride - tablet, extended release;oral)
Manufacturer: VALEANT INTL
Approval date: February 6, 2003
Strength(s): 120MG [RLD] [AB], 180MG [RLD] [AB], 240MG [RLD] [AB], 300MG [RLD] [AB], 360MG [RLD] [AB], 420MG [RLD] [AB]
Has a generic version of Cardizem LA been approved?
A generic version of Cardizem LA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cardizem LA and have been approved by the FDA:
Manufacturer: ACTAVIS LABS FL INC
Approval date: March 15, 2010
Strength(s): 120MG [AB], 180MG [AB], 240MG [AB], 300MG [AB], 360MG [AB], 420MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cardizem LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Cushioning wax beads for making solid shaped articles
Issued: August 2, 2005
Inventor(s): Remon; Jean Paul
Assignee(s): Universiteit Gent
Biologically inactive cushioning beads comprise at least one compressible cushioning component consisting essentially of a microcrystalline hydrocarbon wax or a natural wax, the said wax being at least 30% by weight of the biologically inactive cushioning beads. Such beads are useful for making solid shaped articles containing biologically active ingredients by compression.
Patent expiration dates:
- February 25, 2021✓
- February 25, 2021
Chronotherapeutic diltiazem formulations and the administration thereof
Issued: September 19, 2006
Inventor(s): Albert; Kenneth Stephen & Maes; Paul José
Assignee(s): Biovall Laboratories International SRL
A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
Patent expiration dates:
- December 17, 2019✓✓
- December 17, 2019
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Cardizem LA (diltiazem)
- Cardizem LA Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- 1 Review
- Drug class: calcium channel blocking agents
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AB||Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.|